Guanhao Biotech Co.,Ltd. (SHE:300238)

China flag China · Delayed Price · Currency is CNY
14.43
+0.21 (1.48%)
Apr 29, 2026, 3:04 PM CST
16.46%
Market Cap 3.83B
Revenue (ttm) 387.75M
Net Income (ttm) 24.35M
Shares Out 265.16M
EPS (ttm) 0.09
PE Ratio 160.33
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,915,970
Average Volume 6,558,616
Open 14.11
Previous Close 14.22
Day's Range 14.09 - 14.54
52-Week Range 12.24 - 19.98
Beta 0.39
RSI 42.00
Earnings Date Apr 29, 2026

About Guanhao Biotech

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream for psoriasis. In addit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 535
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300238
Full Company Profile

Financial Performance

In 2025, Guanhao Biotech's revenue was 387.75 million, an increase of 2.72% compared to the previous year's 377.48 million. Earnings were 24.35 million, a decrease of -11.20%.

Financial Statements

News

There is no news available yet.